Should We Treat Stroke Percutaneously in TAVR?

Since its inception, transcatheter aortic valve replacement (TAVR) has improved greatly. However, there still are five big challenges to be solved: paravalvular leak, conduction disturbances, debilitating stroke, impaired kidney function, and major vascular complications and bleeding.

¿Debemos realizar tratamiento percutáneo de los strokes en el TAVI?

Most cases of stroke are periprocedural and ischemic. So far, they have not been well analyzed in terms of their severity and resulting level of impairment in abilities. We also do not know which is the best treatment for each particular case.

The analysis included a total of 387 patients with stroke. Of these, 349 received conservative treatment (CT) and 39 received neurointervention (NI).

Stroke events were classified according to the National Institutes of Health Stroke Scale (NIHSS). Mild stroke had a score 0-5, moderate stroke had a score 6-14, and severe stroke were all events with a score ≥15.

Mean patient age was 81 years old; 52% of patients were male, 35% had diabetes, 13% had undergone previous myocardial revascularization surgery, 17% had experienced a previous infarction, 33% had undergone previous coronary angioplasty, and 35% had atrial fibrillation. The Society of Thoracic Surgeons mortality score was 5.9%.

Read also: RIPCORD 2 Study: Routine Assessment Using Pressure Wires in Acute Coronary Syndrome

Out of the patients who underwent TAVR, 12% did so in their bicuspid aortic valve, and 1.6% were valve-in-valve.

General anesthesia was used in 35% of cases, and self-expandable valves in 61%.

Stroke occurred within the first day (0-2 days). 

The most frequent stroke severity was mild, in 146 patients (49.6%), followed by severe in 75 (25.6%) and moderate in 73 (24.8%). The middle cerebral artery was the most frequently affected artery.

Read also: Are FFR and IVUS Similar to Assess Intermediate Lesions?

The NIHSS score was higher in patients who received NI (4 vs. 14 p < 0.001), and this strategy was used more frequently in cases of moderate or severe stroke (109 in the TC group and 36 in the NI arm).

Overall mortality at 30 days was 23.1%, at 6 months was 35%, and at 1 year was 42.1%. Moderate and severe stroke had a mortality 1.3 and 4.99 times higher compared with mild stroke, respectively.

There was no difference in mortality according to the degree of stroke severity between the two strategies at follow-up.

Read also: Is TCA Useful for Severe Impairment of Left Ventricular Ejection Fraction?

A logistic regression analysis was conducted and it showed that, in cases of severe stroke, the NI strategy increased 2.9 times the chance of survival at 90 days.

Conclusion

Acute ischemic stroke after TAVR has a high morbimortality risk correlated with stroke severity. Findings from this analysis suggest that patients with moderate or severe stroke could potentially improve with time after the intervention. It also highlights the importance of collaboration between cardiologists and neurologists to improve the evolution of acute ischemic stroke after TAVR.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Management and Outcome of Acute Ischemic Stroke Complicating Transcatheter Aortic Valve Replacement. on Behalf of the ASTRO-TAVI Study Group.

Reference: Amos Levi, et al. J Am Coll Cardiol Intv 2022. Article in Press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...